SBIR-STTR Award

Bactericidal agents for slow-growing bacteria
Award last edited on: 6/11/09

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$376,280
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Penelope N Markham

Company Information

Influx Inc

2201 West Campbell Park Drive Suite 116/
Chicago, IL 60612
   (312) 492-7760
   info@influxpharma.com
   www.influxpharma.com
Location: Single
Congr. District: 07
County: Cook

Phase I

Contract Number: 1R43AI052672-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2003
Phase I Amount
$126,280
In many chronic infections, including all biofilm related infections, the slow growth of bacteria is believed to account not only for resistance to antibiotics, but also for the high incidence of persistence and relapse. Considering that all currently prescribed antibiotics are significantly more effective against rapidly growing pathogens, the development of antibiotics highly effective against bacteria in the slow mode of growth is of utmost importance. By screening a chemical library for compounds bactericidal for slow-growing S. aureus, we have succeeded in identifying a very promising class of compounds, pyridinium thiol ethers (PTEs). Preliminary data indicate that PTEs are not only effective against fluid-phase S. aureus, but also against biofilms as well as against other bacteria in a slow mode of growth. In the proposed Phase I project, we will synthesize and screen a library of PTEs in order to identify compounds that will be bactericidal against slow and logarithmically growing S. aureus. Feasibility of the medical use of the most active derivatives will be analyzed. Finally, the basic principles underlying the molecular mechanism of action of PTE compounds will be investigated. The Phase I project will provide the basis for the Phase II project, which will involve chemical improvement of the lead compounds, investigation of their activity in various biofilm models, and in vivo toxicology studies. PTE compounds could provide a unique opportunity for eradication of infections associated with slow bacterial growth

Phase II

Contract Number: 6R43AI052672-02
Start Date: 5/1/03    Completed: 10/31/04
Phase II year
2003
Phase II Amount
$250,000
In many chronic infections, including all biofilm related infections, the slow growth of bacteria is believed to account not only for resistance to antibiotics, but also for the high incidence of persistence and relapse. Considering that all currently prescribed antibiotics are significantly more effective against rapidly growing pathogens, the development of antibiotics highly effective against bacteria in the slow mode of growth is of utmost importance. By screening a chemical library for compounds bactericidal for slow-growing S. aureus, we have succeeded in identifying a very promising class of compounds, pyridinium thiol ethers (PTEs). Preliminary data indicate that PTEs are not only effective against fluid-phase S. aureus, but also against biofilms as well as against other bacteria in a slow mode of growth. In the proposed Phase I project, we will synthesize and screen a library of PTEs in order to identify compounds that will be bactericidal against slow and logarithmically growing S. aureus. Feasibility of the medical use of the most active derivatives will be analyzed. Finally, the basic principles underlying the molecular mechanism of action of PTE compounds will be investigated. The Phase I project will provide the basis for the Phase II project, which will involve chemical improvement of the lead compounds, investigation of their activity in various biofilm models, and in vivo toxicology studies. PTE compounds could provide a unique opportunity for eradication of infections associated with slow bacterial growth.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Staphylococcus Aureus, Antibacterial Agent, Biofilm, Drug Design /Synthesis /Production, Pyridine Cell Growth Regulation, Chemical Registry /Resource, Drug Screening /Evaluation, Thioether Cell Line, Human Tissue